Abstract: The disclosure provides compounds comprising a ?-ketoamide linkage that is terminated on each end by an amino acid, such as compounds of Formula (I), wherein RA-RC are defined herein. Also provided are compositions containing these compounds and methods of inhibiting calpain activity, treating a calpain-mediated disorder, inhibiting cathepsin-B, cathepsin-L, cathepsin-S, or cathepsin-L activity, and methods of treating a cathepsin-B, cathepsin-L, cathepsin-S, or cathepsin-L mediated disorder using these compounds and compositions.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections.

Abstract: The invention is directed to novel pyranoindole derivatives and analogs as well as compositions containing the same and to the use thereof for the treatment, prevention or inhibition of viral infections and associated diseases caused by the Hepatitis C virus.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections.

Abstract: The corrosion of metals in contact with aqueous alkanolamine solution in acid gas removal units is inhibited by adding to the alkanolamine solution a corrosion inhibiting amount of a thiacrown ether compound. The compounds are monomeric or polymeric and have from 4 to about 10 sulfur atoms on each of the crown rings. The polymeric thiacrown ether ring structures are substituted with polymerized ethylenically unsaturated monomers and have from 4 to about 10 sulfur atoms on each of the crown rings. In some embodiments of the invention, a linkage “M” connects the thiacrown ether ring structures and the polymers and M is O; S; COO; C1 to C5 substituted or unsubstituted linear or branched alkylene wherein the substituent is OH, SH, F, Br, Cl, I, COOH, amine, mono- or di- C1 to C5 alkylamino, C1 to C3 lower alkanoylamino or nitro; or M is NR6 where R6 is H or C1 to C5 alkyl.

Abstract: Thiacrown ether and polymeric thiacrown ether compounds are disclosed. The thiacrown ether ring structures are substituted and have from 4 to about 10 sulfur atoms on each of the crown rings. The polymeric thiacrown ether ring structures are substituted with polymers and have from 4 to about 10 sulfur atoms on each of the crown rings. The thiacrown compounds of the present invention are expected to have utility in a wide range of applications including but not limited to utility as metal ion chelating, sequestering, and complexing agents. The thiacrown compounds are also expected to have utility as corrosion inhibitors for cooling tower, boiler, and waste water systems, hydrocarbon process systems and metal surface treatments systems.